Fulgent Genetics, Inc. (FLGT) fair value analysis
Nasdaq · Updated 2026-10-19
FLGT price how computed
Valuation status
No fair-value estimate yetFLGT has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for FLGT yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $19.81
- Sector
- Healthcare
- 12-month range
- $13.79–$30.85
- Market cap
- $545M
- From 52-week high
- -35.8%
- Shares outstanding
- 27.5M
- Rank in Healthcare by quality score
- #145 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Fulgent Genetics, Inc. is a healthcare company that provides genetic testing and sequencing services to help diagnose and identify genetic disorders in patients. The company operates laboratories and serves clients across the United States and internationally.
FLGT currently ranks #145 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $545M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $324M
- Net margin
- -26.0%
- EPS (TTM)
- $-0.94
- Gross margin
- 30.1%
- Debt / equity
- 0.01
- Revenue growth (3-yr avg)
- 0.3%
- Shares outstanding
- 27.5M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 37 · neutral
- 50-day average
- $20.46
- 200-day average
- $19.70
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-06
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▼ miss (-11.4%)
2026-03 ▼ miss (-2.9%)
2025-12 ▲ beat (+365.8%)
2025-09 ▲ beat (+163.6%)
2025-06 ▲ beat (+138.9%)
2025-03 ▲ beat (+122.2%)
2024-12 ▲ beat (+110.8%)
2024-09 ▲ beat (+306.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 0 buy · 1 hold · 0 sell (1 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $19
- Target vs last price
- -4.1%
What our data shows for FLGT
- Shares are trading in the middle of their 12-month price range of $13.79–$30.85.
- The 14-day relative strength index sits at a neutral 37.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- FLGT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the FLGT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — # FLGT Healthcare Sector Changes TickrTrends' derived indicators for FLGT show a shift in the 50/200-day trend state this week, moving from an uptrend to a mixed trend condition. The stock's valuation verdict remains awaiting full valuation as of the current assessment period.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for FLGT showed a shift this week as the 50/200-day trend state moved from mixed to uptrend. The Healthcare sector stock's valuation verdict remains awaiting full valuation. This uptrend development represents a technical change in the stock's intermediate-term momentum trajectory compared to the prior week's mixed positioning.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is FLGT stock undervalued?
TickrTrends has no fair-value estimate for FLGT yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is FLGT's TickrTrends verdict?
FLGT is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does FLGT compare to other Healthcare stocks?
FLGT ranks #145 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is FLGT overbought or oversold?
FLGT's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does FLGT report earnings next?
FLGT's next earnings report is scheduled for 2026-11-06, per the published earnings calendar.
Does FLGT usually beat earnings estimates?
Over its last 8 reported quarters FLGT beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about FLGT?
Of 1 analysts covering FLGT, 0 rate it a buy, 1 a hold and 0 a sell - hold-leaning, with a consensus price target of $19 (-4.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.